• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine

byArnav Agarwal, MDandAliya Ramjaun
September 28, 2019
in Chronic Disease, Nephrology, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Non-drug interventions highly efficacious at reducing depressive symptoms in people with dementia

2 Minute Medicine Rewind September 23, 2019

Donepezil and vitamin E in Alzheimer’s disease [Classics Series]

1. Donepezil is associated with an elevated short-term risk of hospital admission for rhabdomyolysis compared to rivastigmine or galantamine for Alzheimer’s disease and dementia.

Evidence Rating Level: 2 (Good)

Regulatory agencies have issued a post-marketing surveillance warning regarding the risk of rhabdomyolysis with donepezil use, commonly used in managing symptoms of Alzheimer’s disease and dementia. The Pharmacovigilance Databases of the United States and Canada data indicated that such events occurred more frequently with donepezil than with other cholinesterase inhibitors. It is unclear whether rivastigmine and galantamine are associated with a risk of rhabdomyolysis. In this population-based retrospective cohort study from Ontario, Canada (2002-2017), researchers examined whether the initiation of donepezil was associated with a higher risk of 30-day hospital admission with rhabdomyolysis compared to rivastigmine and galantamine in patients age 66 years or older. Overall, records from 152,300 patients with newly dispensed prescriptions for donepezil and 68,053 patients with prescriptions for rivastigmine or galantamine were analyzed. Researchers found that donepezil was associated with a higher risk of rhabdomyolysis-associated hospital admission (88 events, 0.06%) compared to rivastigmine or galantamine (16 events, 0.02%) (weighted OR 2.21, 95% CI 1.52 to 3.22). The majority of hospital admissions following donepezil prescription were not severe. The findings of this study therefore indicate that donepezil may be associated with an elevated short-term risk of hospital admission for non-severe rhabdomyolysis compared to other commonly used agents.

Click to read the study in CMAJ

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cholinesterase inhibitordonepezilgalantaminerhabdomyolysisrivastigmine
Previous Post

Insulin discontinuation among patients over 75 more common in healthier patients

Next Post

Quick Take: Glycemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY)

RelatedReports

Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine
Chronic Disease

Non-drug interventions highly efficacious at reducing depressive symptoms in people with dementia

April 30, 2021
Transthoracic echocardiography can rule out endocarditis in low-risk bacteremic patients
Weekly Rewinds

2 Minute Medicine Rewind September 23, 2019

October 1, 2019
Classics Series, Landmark Trials in Medicine
General Medicine Classics

Donepezil and vitamin E in Alzheimer’s disease [Classics Series]

March 12, 2014
Next Post
Pediatric DKA associated with recent acute care visits

Quick Take: Glycemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY)

Blood pressure variability associated with cardiovascular disease and mortality

Quick Take: Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER)

2 Minute Medicine Rewind September 30, 2019

2 Minute Medicine Rewind September 30, 2019

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Similar perinatal outcomes observed amongst conception via natural and assisted reproductive means
  • Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus
  • Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options